{"id":8672,"date":"2025-04-07T18:31:38","date_gmt":"2025-04-07T18:31:38","guid":{"rendered":"https:\/\/hnetalk.com\/provider\/?p=8672"},"modified":"2025-04-07T18:31:38","modified_gmt":"2025-04-07T18:31:38","slug":"masshealth-drug-utilization-review-dur-program","status":"publish","type":"post","link":"http:\/\/hnetalk.com\/provider\/masshealth-drug-utilization-review-dur-program\/","title":{"rendered":"MassHealth Drug Utilization Review (DUR) Program"},"content":{"rendered":"<table width=\"0\">\n<thead>\n<tr>\n<td width=\"198\"><strong>Updates<\/strong><\/td>\n<td width=\"551\"><strong>Notes<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"198\"><strong>MassHealth<\/strong><\/p>\n<p><strong>\u00a0<\/strong><\/td>\n<td width=\"551\"><strong>All CAR-T drugs transition to the MassHealth Drug Utilization Review (DUR) Program<\/strong><\/p>\n<ul>\n<li>Effective April 1, 2025, MassHealth will transition the review and management of all CAR-T drugs to the MassHealth Drug Utilization Review (DUR) Program.<\/li>\n<li>Health New England will continue to review all other services related to CAR-T.<\/li>\n<li>The Chimeric Antigen Receptor Therapy policy will be updated to reflect this change.<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Updates Notes MassHealth \u00a0 All CAR-T drugs transition to the MassHealth Drug Utilization Review (DUR) Program Effective April 1, 2025, MassHealth will transition the review and management of all CAR-T drugs to the MassHealth Drug Utilization Review (DUR) Program. Health New England will continue to review all other services related to CAR-T. The Chimeric Antigen [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[92],"tags":[],"class_list":["post-8672","post","type-post","status-publish","format-standard","hentry","category-provider-newsletter"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p6ZZHB-2fS","_links":{"self":[{"href":"http:\/\/hnetalk.com\/provider\/wp-json\/wp\/v2\/posts\/8672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/hnetalk.com\/provider\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/hnetalk.com\/provider\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/hnetalk.com\/provider\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"http:\/\/hnetalk.com\/provider\/wp-json\/wp\/v2\/comments?post=8672"}],"version-history":[{"count":2,"href":"http:\/\/hnetalk.com\/provider\/wp-json\/wp\/v2\/posts\/8672\/revisions"}],"predecessor-version":[{"id":8674,"href":"http:\/\/hnetalk.com\/provider\/wp-json\/wp\/v2\/posts\/8672\/revisions\/8674"}],"wp:attachment":[{"href":"http:\/\/hnetalk.com\/provider\/wp-json\/wp\/v2\/media?parent=8672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/hnetalk.com\/provider\/wp-json\/wp\/v2\/categories?post=8672"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/hnetalk.com\/provider\/wp-json\/wp\/v2\/tags?post=8672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}